Email Alert RSS
Volume 14 Issue 1
Jan.  2023
Turn off MathJax
Article Contents
Abstract
References
Related Articles
LI Yi, XU Yingchun. A New Chapter in the COVID-19 Pandemic: the Characteristics of Omicron Variant and A New Step for Scientific Epidemic Prevention and Control[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 9-17. DOI: 10.12290/xhyxzz.2022-0697
Citation: LI Yi, XU Yingchun. A New Chapter in the COVID-19 Pandemic: the Characteristics of Omicron Variant and A New Step for Scientific Epidemic Prevention and Control[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 9-17. DOI: 10.12290/xhyxzz.2022-0697
shu

A New Chapter in the COVID-19 Pandemic: the Characteristics of Omicron Variant and A New Step for Scientific Epidemic Prevention and Control

  • 1.

    Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 3.

    Graduate School, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-074

Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences 2021-I2M-1-038

Beijing Key Clinical Specialty for Laboratory Medicine -Excellent Project 2K201000

More Information
  • Corresponding author:

    XU Yingchun, E-mail: xycpumch@139.com

  • Received Date: December 05, 2022
  • Accepted Date: December 19, 2022
  • Available Online: December 25, 2022
  • Issue Publish Date: January 29, 2023
    Graphical Abstract
    • Abstract
  • Since the outbreak of COVID-19, SARS-CoV-2 has continued to evolve. As the fifth variants of concern (VOCs) announced by the World Health Organization, Omicron has significantly changed from previous VOCs in terms of genome, biological and epidemiological characteristics. Although the severe illness and mortality caused by Omicron infection are significantly lower than those caused by the previous VOCs, Omicron's strong transmission ability has continued to break through the epidemic prevention barrier and human immunity barrier established by prior infections and vaccines. Omicron has opened a new chapter in the COVID-19 pandemic. In this paper, we review the changes in genome and biological characteristics of Omicron and its subspecies as well as the differences in epidemiological characteristics between Omicron and influenza viruses in order to provide scientific basis for the optimization of epidemic prevention and control.
    • FullText(HTML)
    • References (67)
  • [1]
    World Health Organization. SARS-CoV-2 variants of concern and variants of interest[EB/OL]. [2022-12-06]. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
    [2]
    Berkhout B, Herrera-Carrillo E. SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant[J]. J Virol, 2022, 96: e0009022. DOI: 10.1128/jvi.00090-22
    [3]
    Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B. 1.1.529 leads to widespread escape from neutralizing antibody responses[J]. Cell, 2022, 185: 467-484. e15. DOI: 10.1016/j.cell.2021.12.046
    [4]
    Chen J, Wang R, Gilby NB, et al. Omicron Variant (B. 1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance[J]. J Chem Inf Model, 2022, 62: 412-422. DOI: 10.1021/acs.jcim.1c01451
    [5]
    Mannar D, Saville JW, Zhu X, et al. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex[J]. Science, 2022, 375: 760-764. DOI: 10.1126/science.abn7760
    [6]
    Tegally H, Moir M, Everatt J, et al. Emergence of SARS-CoV-2 Omicron lineages BA. 4 and BA. 5 in South Africa[J]. Nat Med, 2022, 28: 1785-1790. DOI: 10.1038/s41591-022-01911-2
    [7]
    World Health Organization. Weekly epidemiological update on Covid-19-23 November 2022[EB/OL]. (2022-11-23)[2022-12-06] https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-23-nove-mber-2022.
    [8]
    Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen evolution[J]. Bioinformatics, 2018, 34: 4121-4123. DOI: 10.1093/bioinformatics/bty407
    [9]
    Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization[J]. Nature, 2022, 602: 671-675. DOI: 10.1038/s41586-021-04389-z
    [10]
    Simon-Loriere E, Schwartz O. Towards SARS-CoV-2 serotypes?[J]. Nat Rev Microbiol, 2022, 20: 187-188. DOI: 10.1038/s41579-022-00708-x
    [11]
    Wilks SH, Mühlemann B, Shen X, et al. Mapping SARS-CoV-2 antigenic relationships and serological responses[J]. bioRxiv, 2022. doi: 10.1101/2022.01.28.477987.
    [12]
    Thakur V, Ratho RK. OMICRON (B. 1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear[J]. J Med Virol, 2022, 94: 1821-1824. DOI: 10.1002/jmv.27541
    [13]
    Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observa-tional study from the ZOE COVID Study[J]. Lancet, 2022, 399: 1618-1624. DOI: 10.1016/S0140-6736(22)00327-0
    [14]
    Kim MK, Lee B, Choi YY, et al. Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea[J]. J Korean Med Sci, 2022, 37: e31. DOI: 10.3346/jkms.2022.37.e31
    [15]
    Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study[J]. Lancet, 2022, 399: 437-446. DOI: 10.1016/S0140-6736(22)00017-4
    [16]
    Lewnard JA, Hong VX, Patel MM, et al. Clinical outcomes associated with SARS-CoV-2 Omicron (B. 1.1.529) variant and BA. 1/BA. 1.1 or BA. 2 subvariant infection in Southern California[J]. Nat Med, 2022, 28: 1933-1943. DOI: 10.1038/s41591-022-01887-z
    [17]
    Jassat W, Abdool Karim SS, Mudara C, et al. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study[J]. Lancet Glob Health, 2022, 10: e961-e969. DOI: 10.1016/S2214-109X(22)00114-0
    [18]
    World Health Organization. Severity of disease associated with Omicron variant as compared with Delta variant in hospitalized patients with suspected or confirmed SARS-CoV-2 infection[EB/OL]. (2022-06-07)[2022-12-06]. https://www.who.int/publications/i/item/9789240051829.
    [19]
    Ulloa AC, Buchan SA, Daneman N, et al. Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada[J]. JAMA, 2022, 327: 1286-1288. DOI: 10.1001/jama.2022.2274
    [20]
    Strasser ZH, Greifer N, Hadavand A, et al. Estimates of SARS-CoV-2 Omicron BA. 2 Subvariant Severity in New England[J]. JAMA Netw Open, 2022, 5: e2238354. DOI: 10.1001/jamanetworkopen.2022.38354
    [21]
    Davies MA, Morden E, Rosseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA. 4 and BA. 5 compared with previous waves in the Western Cape Province, South Africa[J]. Int J Infect Dis, 2022. doi: 10.1101/2022.06.28.22276983.
    [22]
    Callaway E. What Omicron's BA. 4 and BA. 5 variants mean for the pandemic[J]. Nature, 2022, 606: 848-849. DOI: 10.1038/d41586-022-01730-y
    [23]
    Bentley EG, Kirby A, Sharma P, et al. SARS-CoV-2 Omicron-B. 1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19[J]. bioRxiv, 2021. doi: https://doi.org/10.1101/2021.12.26.474085.
    [24]
    Hui KPY, Ho JCW, Cheung MC, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo[J]. Nature, 2022, 603: 715-720. DOI: 10.1038/s41586-022-04479-6
    [25]
    Brüssow H. COVID-19: Omicron-the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2[J]. Microb Biotechnol, 2022, 15: 1927-1939. DOI: 10.1111/1751-7915.14064
    [26]
    Peacock TP, Brown JC, Zhou J, et al. The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein[J]. bioRxiv, 2022: 2021.12.31.474653.
    [27]
    Meng B, Abdullahi A, Ferreira I, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity[J]. Nature, 2022, 603: 706-714. DOI: 10.1038/s41586-022-04474-x
    [28]
    Goga A, Bekker LG, Garrett N, et al. Breakthrough Covid-19 infections during periods of circulating Beta, Delta and Omicron variants of concern, among health care workers in the Sisonke Ad26. COV2. S vaccine trial, South Africa[J]. medRxiv, 2021: 2021.12.21.21268171.
    [29]
    Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection[J]. N Engl J Med, 2022, 386: 1288-1290. DOI: 10.1056/NEJMc2200133
    [30]
    Khan K, Karim F, Ganga Y, et al. Omicron BA. 4/BA. 5 escape neutralizing immunity elicited by BA. 1 infection[J]. Nat Commun, 2022, 13: 4686. DOI: 10.1038/s41467-022-32396-9
    [31]
    Ohashi H, Hishiki T, Akazawa D, et al. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA. 1 and BA. 2[J]. Antiviral Res, 2022, 205: 105372. DOI: 10.1016/j.antiviral.2022.105372
    [32]
    Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA. 2[J]. N Engl J Med, 2022, 386: 1475-1477. DOI: 10.1056/NEJMc2201933
    [33]
    Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12.1, BA. 4 and BA. 5[J]. Nature, 2022, 608: 603-608.
    [34]
    Yu J, Collier AY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA. 1 and BA. 2 Variants[J]. N Engl J Med, 2022, 386: 1579-1580. DOI: 10.1056/NEJMc2201849
    [35]
    Kurhade C, Zou J, Xia H, et al. Neutralization of Omicron BA. 1, BA. 2, and BA. 3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine[J]. Nat Commun, 2022, 13: 3602. DOI: 10.1038/s41467-022-30681-1
    [36]
    Chemaitelly H, Abu-Raddad LJ. Waning effectiveness of COVID-19 vaccines[J]. Lancet, 2022, 399: 771-773. DOI: 10.1016/S0140-6736(22)00277-X
    [37]
    Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA. 2.12.1, BA. 4, and BA. 5[J]. N Engl J Med, 2022, 387: 86-88. DOI: 10.1056/NEJMc2206576
    [38]
    Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum[J]. Cell, 2022, 185: 2422-2433. e13. DOI: 10.1016/j.cell.2022.06.005
    [39]
    Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic[J]. Lancet, 2021, 398: 2126-2128. DOI: 10.1016/S0140-6736(21)02758-6
    [40]
    Redd AD, Nardin A, Kared H, et al. Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8(+) T-Cell Epitopes Identified in COVID-19 Convalescent Individuals[J]. mBio, 2022, 13: e0361721. DOI: 10.1128/mbio.03617-21
    [41]
    Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19[J]. Nat Med, 2020, 26: 842-844. DOI: 10.1038/s41591-020-0901-9
    [42]
    Liu J, Chandrashekar A, Sellers D, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron[J]. Nature, 2022, 603: 493-496. DOI: 10.1038/s41586-022-04465-y
    [43]
    Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron[J]. Cell, 2022, 185: 847-859. e11. DOI: 10.1016/j.cell.2022.01.015
    [44]
    Kirsebom FCM, Andrews N, Stowe J, et al. COVID-19 vaccine effectiveness against the omicron (BA. 2) variant in England[J]. Lancet Infect Dis, 2022, 22: 931-933. DOI: 10.1016/S1473-3099(22)00309-7
    [45]
    Cheung PH, Chan CP, Jin DY. Lessons learned from the fifth wave of COVID-19 in Hong Kong in early 2022[J]. Emerg Microbes Infect, 2022, 11: 1072-1078. DOI: 10.1080/22221751.2022.2060137
    [46]
    Ministry of Health, Singapore. COVID-19 Statistics[EB/OL]. [2022-12-06]. https://www.moh.gov.sg/COVID-19/statistics.
    [47]
    McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study[J]. Lancet Infect Dis, 2022, 22: 1435-1443. DOI: 10.1016/S1473-3099(22)00345-0
    [48]
    Xu H, Li H, You H, et al. Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: Real-world study in Jilin Province, China[J]. Emerg Microbes Infect, 2022: 1-30.
    [49]
    Zhang X, Zhang W, Chen S. Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic[J]. Lancet, 2022, 399: 2011-2012. DOI: 10.1016/S0140-6736(22)00838-8
    [50]
    Domingo FR, Waddell LA, Cheung AM, et al. Prevalence of long-term effects in individuals diagnosed with COVID-19: an updated living systematic review[J]. medRxiv, 2021: 2021.06.03.21258317.
    [51]
    Wulf Hanson S, Abbafati C, Aerts JG, et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021[J]. JAMA, 2022, 328: 1604-1615. DOI: 10.1001/jama.2022.18931
    [52]
    Hastie CE, Lowe DJ, McAuley A, et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study[J]. Nat Commun, 2022, 13: 5663. DOI: 10.1038/s41467-022-33415-5
    [53]
    Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study[J]. Lancet Infect Dis, 2022, 22: 43-55. DOI: 10.1016/S1473-3099(21)00460-6
    [54]
    Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms after COVID-19 vaccination: community based cohort study[J]. Bmj, 2022, 377: e069676.
    [55]
    Antonelli M, Pujol JC, Spector TD, et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2[J]. Lancet, 2022, 399: 2263-2264. DOI: 10.1016/S0140-6736(22)00941-2
    [56]
    Faust JS, Del Rio C. Assessment of Deaths From COVID-19 and From Seasonal Influenza[J]. JAMA Intern Med, 2020, 180: 1045-1046. DOI: 10.1001/jamainternmed.2020.2306
    [57]
    Ludwig M, Jacob J, Basedow F, et al. Clinical outcomes and characteristics of patients hospitalized for Influenza or COVID-19 in Germany[J]. Int J Infect Dis, 2021, 103: 316-322. DOI: 10.1016/j.ijid.2020.11.204
    [58]
    Xue L, Jing S, Zhang K, et al. Infectivity versus fatality of SARS-CoV-2 mutations and influenza[J]. Int J Infect Dis, 2022, 121: 195-202. DOI: 10.1016/j.ijid.2022.05.031
    [59]
    Jay Hilotin, Vijith Pulikkal. COVID-19: Omicron now less deadly than flu?[EB/OL]. (2022-3-11)[2022-12-06]. https://gulfnews.com/special-reports/COVID-19-omicron-now-less-deadly-than-flu-1.1647011926766.
    [60]
    Bilinski A, Thompson K, Emanuel E. COVID-19 and Excess All-Cause Mortality in the US and 20 Comparison Countries, June 2021-March 2022[J]. JAMA, 2022. doi: 10.1001/jama.2022.21795.
    [61]
    Ministry of Health (Singapore). COVID-19 Situation at a Glance[EB/OL]. [2022-12-06] https://www.moh.gov.sg/.
    [62]
    Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study[J]. Lancet, 2018, 391: 1285-1300. DOI: 10.1016/S0140-6736(17)33293-2
    [63]
    Li ZJ, Yu LJ, Zhang HY, et al. Broad Impacts of Coronavirus Disease 2019(COVID-19) Pandemic on Acute Respiratory Infections in China: An Observational Study[J]. Clin Infect Dis, 2022, 75: e1054-e1062. DOI: 10.1093/cid/ciab942
    [64]
    Huang WJ, Cheng YH, Tan MJ, et al. Epidemiological and virological surveillance of influenza viruses in China during 2020-2021[J]. Infect Dis Poverty, 2022, 11: 74. DOI: 10.1186/s40249-022-01002-x
    [65]
    Cohen R, Ashman M, Taha MK, et al. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap?[J]. Infect Dis Now, 2021, 51: 418-423. DOI: 10.1016/j.idnow.2021.05.004
    [66]
    Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 Omicron in China[J]. Nat Med, 2022, 28: 1468-1475. DOI: 10.1038/s41591-022-01855-7
    [67]
    Mallapaty S. Can China avoid a wave of deaths if it lifts strict zero COVID policy?[J]. Nature, 2022, 612: 203. DOI: 10.1038/d41586-022-04235-w
    • Related Articles

  • Related Articles

    [1]YAN Xinchun, HUO Li. Evaluation of Von Hippel-Lindau Syndrome Through Novel Small Molecular Tracer 68Ga-NY104 PET/CT Imaging[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 911-915. DOI: 10.12290/xhyxzz.2024-0216
    [2]ZHANG Ning, YANG Chenhao, ZHOU Liangrui, SUN Xiaohong, LIU Xiaohong, KANG Lin, LI Ji, LI Hailong. Cronkhite-Canada Syndrome Combined with Asymptomatic Novel Coronavirus Infection: A Case Report[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 406-412. DOI: 10.12290/xhyxzz.2023-0476
    [3]LIU Wanrong, TANG Hui, ZHOU Na, QIU Wei, LI Xiaoyuan, WANG Xiang, BAI Chunmei, ZHOU Jianfeng, ZHAO Lin. Incidence of COVID-19 in Patients with Tumor During the Omicron Pandemic[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1238-1245. DOI: 10.12290/xhyxzz.2023-0281
    [4]LIU Huan, HUANG Xiaoling, DAI Mengying, GUO Jiejie, GAO feng. Clinical Characteristics and Inflammatory Markers of Omicron BA.5.2 Variant Infection in Hospitalized Patients and Their Predictive Role in Disease Prognosis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1038-1045. DOI: 10.12290/xhyxzz.2023-0055
    [5]ZHANG Kezhen, JIN Li. Research Progress of the Impact of SARS-CoV-2 on Fertility[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 953-958. DOI: 10.12290/xhyxzz.2023-0289
    [6]CHEN Yuqing, LI Jinming. Virological Characteristics of the Omicron Variant: Key Mutations, Pathogenicity, and Immune Escape[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 945-952. DOI: 10.12290/xhyxzz.2023-0139
    [7]QIU Luyao, TANG Wenjing, YANG Lu, LYU Ge, CHEN Junjie, SUN Gan, WANG Yanping, ZHOU Lina, AN Yunfei, ZHANG Zhiyong, TANG Xuemei, ZHAO Xiaodong, DU Hongqiang. Clinical Phenotype and Immunological Characteristics of A Patient with De Novo Heterozygous Mutation of PTEN[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 373-378. DOI: 10.12290/xhyxzz.2023-0023
    [8]Shuang ZHOU, Yue LI. Castleman Disease Variant of POEMS Syndrome: A Case Report[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 202-206. DOI: 10.3969/j.issn.1674-9081.20170112
    [10]Jie LIU, Yue-ping ZENG, Chun-xia HE, Qin LONG, Hong-zhong JIN, Qiu-ning SUN. Corticosteroids plus Intravenous Immunoglobulin in the Treatment of 7 Cases with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(4): 381-385. DOI: 10.3969/j.issn.1674-9081.2012.04.004

  • Cited by

    Periodical cited type(21)

    1. 王建新，孙明月，吕行，郭曼萍，代欣玥，杨巧宁，申春悌，元唯安，王天芳，连凤梅，刘树林，张磊，谢雁鸣，王忠，王保和，黄宇虹，刘文娜，高蕊. 中医证候疗效评价量表研制指南. 中国新药杂志. 2025(02): 113-122 .
    2. 唐晓颇，姜泉. 基于临床需求的干燥综合征诊疗体系构建与示范应用. 中国中医基础医学杂志. 2025(02): 231-235 .
    3. 杨一玖，张海力，刘斌，梁宁，李慧珍，宋填，曹文杰，胡紫腾，马厚芳，王燕平，韩晟，史楠楠. 中成药特征价格变量指标体系构建研究. 中国卫生经济. 2025(02): 18-23 .
    4. 薛飞飞，郝闻致，陈家旭. 层次分析法在中医证候标准化研究的应用探讨. 中华中医药杂志. 2025(01): 271-274 .
    5. 刘誉，张鹏，尚俊杰. 基于德尔菲法的教师学习科学素养框架构建研究. 现代教育技术. 2025(04): 91-101 .
    6. 潘轶竹，郭默宁，蒋锋，李晓虹，王明刚，肖存利. DRGs背景下基于改良德尔菲法的精神专科医院医疗绩效评价指标体系构建研究. 中国医疗管理科学. 2024(01): 105-111 .
    7. 刘晓雨，刘志华，李京璠，李润泽，王玉曼，薛滨清，张心千，杨倩，杜艳茹. 浊毒证诊断量表的研制与权重赋值——基于德尔菲法及层次分析法. 中医杂志. 2024(07): 684-690 .
    8. 胡卓慕，吴进，方玢茹，毛旭，郭莉萍，朱利明. 《中国叙事医学专家共识(2023)》的德尔菲法研究. 叙事医学. 2024(02): 105-112 .
    9. 黄栖，唐乐微，刘茹茹，林丹，黄佳丽，彭雯清，李一靖，陈燕燕，王毓琴. 基于德尔菲法初步构建急性前葡萄膜炎患者报告结局量表. 中华眼视光学与视觉科学杂志. 2024(07): 507-515 .
    10. 王雅琪，高一城，苏澄元，刘美君，李迅，费宇彤. 临床实践指南中临床问题结构化分级及评价. 中国循证医学杂志. 2024(07): 827-831 .
    11. 梁昌昊，尹丁冉，刘美君，尹冠翔，李迅，王雅琪，刘思岐，佟敏，刘鹏伟，苏祥飞，费宇彤. 中医药指南制订中共识法应用关键要素的定性研究. 协和医学杂志. 2024(04): 942-952 . 本站查看
    12. 车前子，郭敬，佟琳，蔡秋杰，陈琳，李慧珍，张海力，郑丹平，胡明智，宋填，程翠翠，蒋寅，刘晨曦，胡妮娜，张华敏，史楠楠. 基于人用经验的中药新药临床定位研究策略与方法. 中国中医基础医学杂志. 2024(08): 1337-1340 .
    13. 赵越，李宵，薛朝军，白万军，董占军. 医疗机构静脉用药评价与遴选专家共识. 医药导报. 2024(09): 1369-1375 .
    14. 彭蓉晏，孙凌云，刘稼玺，庞英，王子旭，唐末，丁亚丛，梁昌昊，唐丽丽，杨宇飞. 基于改良德尔菲法构建《早中期结直肠癌根治术后中西医结合心理康复干预指南》临床问题. 中国中西医结合杂志. 2024(08): 912-920 .
    15. 马思成，张宸铭，唐硕彤，郝晓慧，刘稳榜，马瑞敏，胡静，王祖龙，孙自学. 中医药治疗精子DNA损伤的德尔菲研究. 中华男科学杂志. 2024(09): 854-860 .
    16. 周旋，方格，马庆宇，李晓娟，李永欣，胡志希，李先涛，陈家旭. 基于德尔菲法和层次分析法的气滞证诊断条目筛选及权重确定. 中医杂志. 2024(21): 2211-2216 .
    17. 吴雪，王文雅，廖星，王永炎. 中医药卫生技术评估实施规范的构建与内容介绍. 中国中药杂志. 2024(20): 5643-5651 .
    18. 孟庆莉，姜德春，李达，纪立伟，刘宪军，冀召帅，陶小妹，王海莲，于晓佳，贾自力，张景富，陈世财，顾红燕. 北京地区基层医疗机构药物治疗管理服务门诊工作实施评价体系构建——基于德尔菲法和层次分析法. 中国医院药学杂志. 2024(24): 2909-2914 .
    19. 中国医师协会外科医师分会肥胖代谢病综合管理与护理专家工作组，中国医师协会外科医师分会肥胖和代谢病外科专家工作组，中国肥胖代谢外科研究协作组. 肥胖代谢外科医学科普中国专家共识(2024版). 中华消化外科杂志. 2024(12): 1471-1478 .
    20. 张红银，朱红梅，张慧琴，姚宏文，朱桂荣，李琳. 云南省静脉用药调配中心工作人员细胞毒药物职业暴露及防护调查分析. 昆明医科大学学报. 2023(07): 105-112 .
    21. 张佳佳，杨超，杜世豪，陈晟，杜朔，赵吉平. 基于制定WFAS《女性尿失禁临床实践指南》探讨改良德尔菲法在针灸指南推荐意见研制过程中的应用价值. 中国针灸. 2023(12): 1449-1453 .

    Other cited types(8)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (821) PDF downloads (227) Cited by(29)
    Related
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

      Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return
      x Close Forever Close